Multiply Labs Raises $75M for Pharma Robots
Multiply Labs has raised $75M to scale robotic clusters that automate biologics manufacturing.
AI can help discover new medicines, but those medicines still have to be manufactured reliably. Multiply Labs is targeting that physical bottleneck.
What happened
Multiply Labs raised a $75 million Series B to scale robotic clusters for biopharmaceutical manufacturing.
Its systems automate parts of production across areas including cell and gene therapies, antibodies, viral vectors and mRNA. The company is building modular robotic infrastructure intended to reduce manual handling in complex manufacturing environments.
Why it matters
Biologics manufacturing is expensive, labour intensive and tightly controlled. Scaling a therapy from laboratory development into repeatable production can become a major constraint, especially for newer modalities.
Automation can potentially improve consistency, throughput and traceability while reducing dependence on specialised manual workflows.
The bigger picture
Physical AI in healthcare is moving beyond surgical robots and laboratory automation into manufacturing.
That matters because faster drug discovery only creates value if production can scale with it. Multiply Labs represents an emerging layer of infrastructure where robotics, software and regulated manufacturing converge.